Bioextrax (BIOEX) Q2 2025 earnings summary

Executive summary

• Focus on key projects with high commercial potential, including partnerships in bioplastics and protein from feathers.

• Extended Letter of Intent with a top global chemical company for PHA in Home & Personal Care, with ongoing positive customer dialogues.

• Delivered first paid feasibility study with Chematur, confirming cost-effectiveness of PHBV technology.

• Advanced to phase 3 in collaboration with a leading sugar producer, validating technology at 1000-liter scale.

• Strengthened board with new member bringing marketing and communication expertise.

Financial highlights

• Q2 2025 net sales: 448 tkr (170 tkr Q2 2024); H1 2025 net sales: 527 tkr (170 tkr H1 2024).

• Q2 2025 operating result: -4,446 tkr (-4,812 tkr Q2 2024); H1 2025: -8,435 tkr (-9,701 tkr H1 2024).

• Q2 2025 EPS: -0.11 SEK (-0.15); H1 2025 EPS: -0.21 SEK (-0.31).

• Cash flow H1 2025: -6,473 tkr (-1,299 tkr H1 2024); cash at period end: 10,794 tkr (17,267 tkr Dec 2024).

• Equity at period end: 17,971 tkr (26,059 tkr Dec 2024); equity per share: 0.45 SEK (0.67 SEK Dec 2024).

Outlook and guidance

• Board assesses liquidity as sufficient for the next 12 months, supported by a recent rights issue and expected license revenue growth.

• Ongoing commercialization efforts with several potential customers and partners.